Publication | Open Access
SIP1/NHERF2 enhances estrogen receptor alpha transactivation in breast cancer cells
17
Citations
31
References
2014
Year
Breast OncologyMolecular RegulationCancer BiologyTumor BiologyTranscriptional RegulationSignaling PathwayCell RegulationMcf7 CellsRadiation OncologyCell SignalingCancer ResearchMolecular SignalingMolecular PhysiologyHormonal ReceptorBreast Cancer CellsGene ExpressionEpigenetic RegulationCell BiologyTranscription RegulationEndocrine-related CancerBreast Cancer TumorsSignal TransductionChromatin StructureNatural SciencesBreast CancerTumor SuppressorSystems BiologyMedicineEstrogen Receptor Alpha
The estrogen receptor alpha (ERα) is a ligand-activated transcription factor that possesses two activating domains designated AF-1 and AF-2 that mediate its transcriptional activity. The role of AF-2 is to recruit coregulator protein complexes capable of modifying chromatin condensation status. In contrast, the mechanism responsible for the ligand-independent AF-1 activity and for its synergistic functional interaction with AF-2 is unclear. In this study, we have identified the protein Na+/H+ Exchanger RegulatoryFactor 2 (NHERF2) as an ERα-associated coactivator that interacts predominantly with the AF-1 domain of the nuclear receptor. Overexpression of NHERF2 in breast cancer MCF7 cells produced an increase in ERα transactivation. Interestingly, the presence of SRC-1 in NHERF2 stably overexpressing MCF7 cells produced a synergistic increase in ERα activity. We show further that NHERF2 interacts with ERα and SRC-1 in the promoter region of ERα target genes. The binding of NHERF2 to ERα in MCF7 cells increased cell proliferation and the ability of MCF7 cells to form tumors in a mouse model. We analyzed the expression of NHERF2 in breast cancer tumors finding a 2- to 17-fold increase in its mRNA levels in 50% of the tumor samples compared to normal breast tissue. These results indicate that NHERF2 is a coactivator of ERα that may participate in the development of estrogen-dependent breast cancer tumors.
| Year | Citations | |
|---|---|---|
Page 1
Page 1